Neuroendocrine Tumors
358
74
107
140
Key Insights
Highlights
Success Rate
81% trial completion
Published Results
57 trials with published results (16%)
Research Maturity
140 completed trials (39% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
8.9%
32 terminated out of 358 trials
81.4%
-5.1% vs benchmark
8%
28 trials in Phase 3/4
41%
57 of 140 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 140 completed trials
Clinical Trials (358)
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Integrated Cancer Repository for Cancer Research
Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
Analysis of Optimal Treatment Sequencing of Surufatinib and Somatostatin Analogs in Neuroendocrine Tumors: A Retrospective Cohort Study
Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients
Agnostic Therapy in Rare Solid Tumors
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors